| Company Name: |
ChemeGen(Shanghai) Biotechnology Co.,Ltd.
|
| Tel: |
18818260767 |
| Email: |
sales@chemegen.com |
| Products Intro: |
Product Name:PSI-7977-13C-d3
CAS:2070009-25-3
Purity:98% Package:10 mg;50 mg;100 mg;500 mg;1 g;5 g;10 g
|
| Company Name: |
CHINA ISOTOPE CO., LIMITED
|
| Tel: |
02151600108 13062666369 |
| Email: |
info@isotopechem.com |
| Products Intro: |
Product Name:PSI-7977-13C-d3
CAS:2070009-25-3
Purity:Purity: >=98% Package:1mg Remarks:CA25045
|
|
| | PSI-7977-13C-d3 Basic information |
| Product Name: | PSI-7977-13C-d3 | | Synonyms: | [13C,2H3]-Sofosbuvir;isopropyl((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-(methyl-13C-d3)tetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alaninate;Sofosbuvir 13CD3Q: What is
Sofosbuvir 13CD3 Q: What is the CAS Number of
Sofosbuvir 13CD3 Q: What is the storage condition of
Sofosbuvir 13CD3 Q: What are the applications of
Sofosbuvir 13CD3;PSI-7977-13C-d3;L-Alanine, N-[[P(S),2′R]-2′-deoxy-2′-fluoro-2′-(methyl-13C-d3)-P-phenyl-5′-uridylyl]-, 1-methylethyl ester;13C,D3-Sofosbuvir | | CAS: | 2070009-25-3 | | MF: | C22H26D3FN3O9P | | MW: | 533.46 | | EINECS: | | | Product Categories: | | | Mol File: | 2070009-25-3.mol |  |
| | PSI-7977-13C-d3 Chemical Properties |
| density | 1.413±0.10 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) | | storage temp. | Store at -20°C | | solubility | DMF: 20 mg/ml,DMSO: 20 mg/ml,Ethanol: 25 mg/ml,PBS (pH 7.2): 0.2 mg/ml | | form | A solid |
| | PSI-7977-13C-d3 Usage And Synthesis |
| Description | PSI-7977-13C-d3 is intended for use as an internal standard for the quantification of PSI-7977 by GC- or LC-MS. PSI-7977 is a phosphoramidate prodrug of PSI-7851, a nucleoside analog that, when phosphorylated, inhibits the RNA-dependent RNA polymerase of hepatitis C virus (EC50 = 92 nM). PSI-7977 is effective in vitro and in vivo. | | Uses | PSI-7977-13CD3 is the isotope labelled analog of PSI-7977. PSI-7977 is a prodrug that is metabolized to the active antiviral agent 2''-deoxy-2''-α-fluoro-β-C-methyluridine-5''-monophosphate and is currently being investigated in phase 3 clinical trials for the treatment of hepatitis C. Studies have profiled PSI-7977 as a nucleotide inhibitor of hepatitis C virus, exerting selective inhibitory effects towards HCV NS5B polymerase. | | References | [1] EISUKE MURAKAMI. Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977.[J]. The Journal of Biological Chemistry, 2010, 285 45: 34337-34347. DOI: 10.1074/jbc.m110.161802
[2] MICHAEL J. SOFIA*. Discovery of a β-d-2′-Deoxy-2′-α-fluoro-2′-β-C-methyluridine Nucleotide Prodrug (PSI-7977) for the Treatment of Hepatitis C Virus[J]. Journal of Medicinal Chemistry, 2010, 53 19: 7202-7218. DOI: 10.1021/jm100863x
[3] ANGELA M LAM. Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus.[J]. Antimicrobial Agents and Chemotherapy, 2012, 56 6: 3359-3368. DOI: 10.1128/aac.00054-12
[4] EDWARD J GANE. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C.[J]. The New England Journal of Medicine, 2013: 34-44. DOI: 10.1056/nejmoa1208953
[5] ERIC LAWITZ. Sofosbuvir for previously untreated chronic hepatitis C infection.[J]. New England Journal of Medicine, 2013, 368 20: 1878-1887. DOI: 10.1056/nejmoa1214853 |
| | PSI-7977-13C-d3 Preparation Products And Raw materials |
|